Spectra pharmaceuticals8/15/2023 Michael Grabow has served as Spectrum’s Executive Vice President and Chief Business Officer since October 2022, overseeing Corporate Strategy, Commercial Operations and Analytics, Business Development, Human Resources, Investor Relations, and IT. Brennan is currently serving as a Director and Audit Chair at Artios Pharma Limited, a privately held biotech company. ![]() in Economics from the University of Illinois at Urbana-Champaign and received her MBA from the University of Chicago Booth School of Business. For the past 15 years she has served on management teams of publicly traded life science companies raising more than $2 billion in capital, building finance organizations and supporting operations from early development stage into commercialization. She was key to the capital markets strategy over a significant period of time and successfully integrated 18 acquisitions leading to significant revenue growth for the company. Brennan spent 11 years as the Senior Vice President of Treasury and Investor Relations at Integra LifeSciences Holdings Corporation, where she served in numerous capacities and led Integra through a myriad of financings. Prior to Fore, she was the Chief Financial Officer of TELA Bio, Inc., where she guided the company through a successful IPO and follow-on financing. Prior to joining Spectrum, she was the Chief Financial Officer of Fore Biotherapeutics, a private precision oncology company pioneering the development of cancer therapies guided by functional genomics. Nora Brennan has served as our Chief Financial Officer since May 2022. Riga is an accredited public company director from UCLA’s Anderson School of Business. Riga holds a bachelor’s degree in Biology and Chemistry from St. He has consistently inspired cross-functional teams to deliver superior performance to create value for Spectrum. Additionally, he has led multiple product launches in the oncology market, delivering innovative cancer care while establishing world class partnerships with key industry stakeholders. The divestiture of seven marketed products infused non-dilutive capital back into the organization and enabled Spectrum to further advance its two cornerstone, value driving assets. Riga has led a strategic shift in the company’s focus from a specialty pharmaceutical company to a development-focused organization. ![]() His executive leadership experience spans across operations, business development, sales, marketing, Six Sigma, manufacturing, and corporate accounts.ĭuring his tenure at Spectrum, Mr. ![]() Throughout his career he has successfully integrated leadership and strategy to create meaningful value. He has leadership experience in various positions at Wyeth Ayerst Pharmaceuticals, Eli Lilly and Company, Amgen Inc. He has over 20 years of diverse pharmaceutical leadership experience. Riga was named Spectrum’s President and Chief Executive Officer on January 1st, 2022. Thomas Riga is Spectrum’s President and Chief Executive Officer.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |